Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin-In Reply

JAMA Oncol. 2019 Jun 1;5(6):911-912. doi: 10.1001/jamaoncol.2019.0630.
No abstract available

Publication types

  • Comment

MeSH terms

  • Aspirin
  • Carcinoma, Hepatocellular*
  • Humans
  • Liver Neoplasms*
  • Risk Assessment
  • Risk Factors

Substances

  • Aspirin